Bionure Farma

Logo Bionure_HD2.png

Contact information

Bionure Farma
Mar Massó
C/ Baldiri Reixac 4-8
Areas of activities
  • A. Health Biotechnology
    • Areas of activity
      • Biodrugs
    • Therapeutic areas
      • Ophtalmology and optometry
      • Central nervous system

Bionure is an early-stage drug development company founded in 2009 (spin-off from Hospital Clínic de Barcelona - IDIBAPS and CSIC) based in Barcelona. We are aimed at developing neuroprotective therapies for the treatment of neurodegenerative diseases, with special focus in Multiple Sclerosis (MS), Acute Optic Neuritis (AON) and Glaucoma (GL).

Products and services

Neurodegenerative diseases are sanitary priority in advanced countries because of its high frequency, social and sanitary costs and the lack of curative therapies.

Available treatments for MS are immunomodulatory drugs, only partially effective and have many side effects. In particular, current treatments for MS are immunomodulatory drugs (modulate the body immune system) that decrease the frequency of relapses and hold up its progression, but they are only partially effective and have many side effects. In the case of AON, the treatment with corticosteroids is barely effective.

In the case of GL, current marketed drugs are IOP-lowering drugs (only reduce intraocular pressure). In these diseases, there are many patients who don't benefit from current therapies.

Bionure develops BN201, a small molecule, first-in-class, neuroprotective drug. It represents a new approach for the treatment of MS, AON and GL, since there is not any neuroprotective drug in the market.

The aim of Bionure is to complete the clinical development of BN201 until Phase IIa (PoC of neuroprotection in humans) asap and close co-development/licensing agreements with other pharmaceutical companies.

BN201 has succesfuly completed a Phase 1 trial in the UK in 2019 that investigated the safety, tolerability and pharmacokinetics of single and multiple doses of BN201 in healthy volunteers. The company plans to initiate a Phase 2a trial in the first quarter of 2020.